Nakata Y, Yoshibayashi M, Yonemura T, Uemoto S, Inomata Y, Tanaka K, Furusho K
Department of Pediatrics, Kyoto University Faculty of Medicine, Kurashiki Central Hospital, Okayama, Japan.
Transplantation. 2000 May 15;69(9):1960-2. doi: 10.1097/00007890-200005150-00039.
Tacrolimus has been used as an immunosuppressive agent in the transplantation of all solid organs. Tacrolimus-induced hypertrophic cardiomyopathy has been reported to be an unusual but serious complication. To elucidate the effects of tacrolimus on myocardial hypertrophy, we studied the relationship between the blood levels of tacrolimus and cardiac wall thickening. Our findings demonstrated that tacrolimus-induced myocardial hypertrophy correlated with tacrolimus blood levels, and that myocardial hypertrophy induced by tacrolimus was reversible. However, no patients developed clinically significant symptoms related to myocardial hypertrophy.
他克莫司已被用作所有实体器官移植中的免疫抑制剂。据报道，他克莫司诱导的肥厚性心肌病是一种罕见但严重的并发症。为了阐明他克莫司对心肌肥厚的影响，我们研究了他克莫司血药浓度与心脏壁增厚之间的关系。我们的研究结果表明，他克莫司诱导的心肌肥厚与他克莫司血药浓度相关，并且他克莫司诱导的心肌肥厚是可逆的。然而，没有患者出现与心肌肥厚相关的具有临床意义的症状。
